As a result of multiple clinical trials and novel treatment concepts in BC, the therapy paradigm has shifted from chemotherapy alone to neoadjuvant therapies, such as anti-HER2-targeted therapy combined with chemotherapy and neoadjuvant endocrine therapy (4, 5). This evidence concerns the gene ERBB2 and breast cancer.